Skip to Content

Cabotegravir Dosage

Medically reviewed by Last updated on Feb 12, 2021.

Applies to the following strengths: 30 mg

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for HIV Infection

30 mg orally once a day

-To be taken with rilpivirine tablets (25 mg orally once a day)
-Oral lead-in should be used for about 1 month (at least 28 days) to assess tolerability of cabotegravir before the initiation of cabotegravir-rilpivirine IM.
-The last oral dose should be administered on the same day injections with cabotegravir-rilpivirine IM are started.
-If a patient plans to miss a scheduled cabotegravir-rilpivirine IM injection by more than 7 days, this drug may be used with rilpivirine tablets once a day to replace up to 2 consecutive monthly injection visits.
---The first dose of oral therapy should be administered about 1 month after the last injection dose of cabotegravir-rilpivirine IM and continued until the day injection dosing is restarted.
---The manufacturer product information for cabotegravir-rilpivirine IM should be consulted regarding resumption of monthly injection dosing.

Uses: In combination with rilpivirine tablets, for short-term treatment of HIV-1 infection in patients who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known/suspected resistance to either cabotegravir or rilpivirine, as:
-Oral lead-in to assess tolerability of this drug before starting cabotegravir-rilpivirine IM
-Oral therapy for patients who will miss planned injection dosing with cabotegravir-rilpivirine IM

Renal Dose Adjustments

Mild to moderate renal dysfunction (CrCl 30 to less than 90 mL/min) or severe renal dysfunction (CrCl less than 30 mL/min): No adjustment recommended.
ESRD (CrCl less than 15 mL/min) not on dialysis: Data not available

Liver Dose Adjustments

Mild or moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Data not available

-This drug has not been studied in patients with severe liver dysfunction.


-Previous hypersensitivity reaction to the active component
-Coadministration with drugs that significantly decrease cabotegravir plasma levels due to UGT1A1 enzyme induction (which may lead to loss of virologic response), including carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifapentine
-Contraindications to rilpivirine

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

-This drug is highly bound to plasma proteins; significant removal via dialysis is unlikely.

Other Comments

Administration advice:
-Consult the manufacturer product information for cabotegravir-rilpivirine IM before starting this drug to ensure treatment with cabotegravir-rilpivirine IM is appropriate.
-Administer this drug with oral rilpivirine at about the same time each day with a meal.
-Consult the manufacturer product information regarding missed doses.

Storage requirements:
-Store below 30C (86F).

-Before starting this drug, healthcare professionals should be aware that use of cabotegravir-rilpivirine IM with rifabutin is contraindicated.
-This drug should not be used in patients with known/suspected resistance to cabotegravir or rilpivirine.
-Dosing for cabotegravir-rilpivirine regimen consists of 3 distinct phases: an oral lead-in with this drug coadministered with rilpivirine tablets (month 1), initiation injections of cabotegravir-rilpivirine IM (month 2), and continuation injections with cabotegravir-rilpivirine IM (month 3 onwards).
-The manufacturer product information for rilpivirine tablets should be consulted.

-Hepatic: Liver chemistries

Patient advice:
-Read the US FDA-approved patient labeling (Patient Information).
-Contact healthcare provider at once if rash develops; stop this drug immediately and seek medical care if rash develops with fever, generally ill feeling, extreme tiredness, muscle/joint aches, blisters, oral blisters/lesions, eye inflammation, facial swelling, swelling of the eyes/lips/tongue/mouth, difficulty breathing, and/or signs/symptoms of liver problems (e.g., yellowing of the skin/whites of the eyes, dark/tea-colored urine, pale-colored stools/bowel movements, nausea, vomiting, loss of appetite, pain/aching/sensitivity on the right side below the ribs).
-It is important to take this drug on a regular dosing schedule with a meal at the same time as oral rilpivirine; avoid missing doses as this can lead to development of resistance.

More about cabotegravir

Consumer resources

Other brands

Professional resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.